Soligenix, Inc. Files 8-K on Delisting Concerns
Ticker: SNGX · Form: 8-K · Filed: Nov 18, 2025 · CIK: 812796
| Field | Detail |
|---|---|
| Company | Soligenix, Inc. (SNGX) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $2,500,000, $7,597,976 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: SNGX
TL;DR
Soligenix might be delisted, filing 8-K on Nov 18, 2025.
AI Summary
Soligenix, Inc. filed an 8-K on November 18, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The filing also includes financial statements and exhibits. The company, formerly known as Dor Biopharma Inc., is incorporated in Delaware and headquartered in Princeton, NJ.
Why It Matters
This filing indicates potential issues with Soligenix, Inc.'s continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.
Key Numbers
- 001-14778 — Commission File Number (Identifies the specific SEC filing)
- 41-1505029 — EIN (Employer Identification Number for Soligenix, Inc.)
Key Players & Entities
- Soligenix, Inc. (company) — Filer of the 8-K report
- November 18, 2025 (date) — Date of the earliest event reported
- Dor Biopharma Inc. (company) — Former company name
- 29 Emmons Drive, Suite B-10, Princeton, NJ 08540 (address) — Company's business and mailing address
FAQ
What specific listing rule or standard has Soligenix, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Soligenix, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been filed.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a notice of delisting or failure to satisfy a continued listing rule or standard, and to include financial statements and exhibits.
When was Soligenix, Inc. formerly known as Dor Biopharma Inc.?
The date of name change from Dor Biopharma Inc. to Soligenix, Inc. is not explicitly stated in this excerpt, but the filing is dated November 18, 2025.
Where is Soligenix, Inc. headquartered?
Soligenix, Inc. is headquartered in Princeton, New Jersey, with its business and mailing address listed as 29 Emmons Drive, Suite B-10, Princeton, NJ 08540.
What is the SIC code for Soligenix, Inc.?
The Standard Industrial Classification (SIC) code for Soligenix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-11-18 16:05:18
Key Financial Figures
- $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"
- $7,597,976 — ompany reported stockholders' equity of $7,597,976, which is above the Stockholders' Equit
Filing Documents
- sngx-20251118x8k.htm (8-K) — 36KB
- 0001104659-25-113645.txt ( ) — 152KB
- sngx-20251118.xsd (EX-101.SCH) — 3KB
- sngx-20251118_def.xml (EX-101.DEF) — 3KB
- sngx-20251118_lab.xml (EX-101.LAB) — 17KB
- sngx-20251118_pre.xml (EX-101.PRE) — 10KB
- sngx-20251118x8k_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Previously Disclosed Background As previously reported, on August 15, 2025, Soligenix, Inc. (the "Company") received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"). In the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, the Company reported stockholders' equity of $7,597,976, which is above the Stockholders' Equity Requirement for continued listing. New Disclosure On November 18, 2025, the Company received a letter from Nasdaq confirming that the Company had regained compliance with the Shareholders' Equity Requirement and that the matter is now closed.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Soligenix, Inc. November 18, 2025 By: /s/ Christopher J. Schaber Christopher J. Schaber, Ph.D. President and Chief Executive Officer (Principal Executive Officer) 3